New study data show that alvimopan -a mu-opioid antagonist that competitively binds to, but doesn't activate, the u-opioid receptor in the gastrointestinal tract -expedites gastrointestinal recovery and improves early outcomes in patients undergoing radical cystectomy and receiving opioids, without increasing the risk of cardiovascular morbidity.For this study, 280patients with bladder cancer were randomized to receive alvimopan (n=143) or placebo (w = 37), as well as postoperative intravenous patient-controlled opioids, after radical surgery at one of 21 high-volume centres in the USA.
展开▼
